Literature DB >> 741207

Plasma C-peptide in uraemic patients.

L Regeur, O K Faber, C Binder.   

Abstract

The kidney has been suggested as the main organ for the degradation of C-peptide. This hypothesis was tested in subjects with normal fasting blood glucose concentration and varying degrees of renal failure. Forty-nine subjects with endogenous creatinine clearance ranging from 0--25 ml/min were studied. The basal steady state concentrations of C-peptide (CP) and the immunoreactivity of insulin (IRI) were determined in plasma from fasting patients. The average IRI was similar to that found in normal subjects while a higher CP was found in all patients but two. The average CP in the nephrectomized patients was six times higher than the mean CP in normal subjects (0.35 pmol/ml). There was a significant inverse correlation between clearance and CP (r = 0.51, P less than 0.001) with the highest CP in nephrectomized patients. It is concluded that the increased CP in renal failure, and especially the markedly increased CP in the nephrectomized group supports the hypothesis of the kidney being the organ mainly responsible for the degradation of C-peptide also in man.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 741207     DOI: 10.3109/00365517809104886

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  9 in total

1.  Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes.

Authors:  Hideo Otsuki; Takeo Kosaka; Kenzo Nakamura; Fumihiko Shimomura; Yoshitaka Kuwahara; Takuji Tsukamoto
Journal:  Int Urol Nephrol       Date:  2013-09-08       Impact factor: 2.370

2.  Outcomes after simultaneous pancreas and kidney transplantation and the discriminative ability of the C-peptide measurement pretransplant among type 1 and type 2 diabetes mellitus.

Authors:  H A Chakkera; J K Bodner; R L Heilman; D C Mulligan; A A Moss; K L Mekeel; M J Mazur; K Hamawi; R M Ray; G L Beck; K S Reddy
Journal:  Transplant Proc       Date:  2010-09       Impact factor: 1.066

3.  Basal and nutrient-stimulated pancreatic and gastrointestinal hormone concentrations in type-1-diabetic patients after successful combined pancreas and kidney transplantation.

Authors:  M A Nauck; M Büsing; C Orskov; E G Siegel; J Talartschik; A Baartz; T Baartz; H Hölzer; U T Hopt; R Ebert
Journal:  Clin Investig       Date:  1992-01

4.  B-cell response to a standardized breakfast in end-stage renal failure.

Authors:  J C Daubresse; P Henrivaux; F Dehout; J C Meunier; A S Luyckx; P J Lefebvre
Journal:  Acta Diabetol Lat       Date:  1985 Jan-Mar

5.  Preserved incretin effect in type 1 diabetic patients with end-stage nephropathy treated by combined heterotopic pancreas and kidney transplantation.

Authors:  M A Nauck; M Büsing; C Orskov; E G Siegel; J Talartschik; A Baartz; T Baartz; U T Hopt; H D Becker; W Creutzfeldt
Journal:  Acta Diabetol       Date:  1993       Impact factor: 4.280

6.  Serum C peptide level and renal function in diabetes mellitus.

Authors:  M N Chowta; P M Adhikari; N K Chowta; A K Shenoy; S D'Souza
Journal:  Indian J Nephrol       Date:  2010-01

7.  Consequences of systemic venous drainage and denervation of heterotopic pancreatic transplants for insulin/C-peptide profiles in the basal state and after oral glucose.

Authors:  M Nauck; M Büsing; E G Siegel; J Talartschik; A Baartz; T Baartz; U T Hopt; H D Becker; W Creutzfeldt
Journal:  Diabetologia       Date:  1991-08       Impact factor: 10.122

8.  Renal and splanchnic exchange of human biosynthetic C-peptide in type 1 (insulin-dependent) diabetes mellitus.

Authors:  S Sjöberg; B L Johansson; J Ostman; J Wahren
Journal:  Diabetologia       Date:  1991-06       Impact factor: 10.122

9.  The effect of hepatitis C virus infection on insulin resistance in chronic haemodialysis patients.

Authors:  Ali Ozdemir; Berrin Yalinbas; Umut Selamet; Meltem Eres; Funda Turkmen; Fatma Kumbasar; Berna Murat; A Tayfun Keskin; Yildiz Barut
Journal:  Yonsei Med J       Date:  2007-04-30       Impact factor: 2.759

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.